Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
2-dose
Ad26.ZEBOV
Ebola vaccine
MVA-BN-Filo
heterologous
homologous
immunogenicity
safety
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
04 09 2022
04 09 2022
Historique:
received:
28
05
2020
accepted:
14
09
2020
pubmed:
18
9
2020
medline:
9
9
2022
entrez:
17
9
2020
Statut:
ppublish
Résumé
This phase 1 placebo-controlled study assessed the safety and immunogenicity of 2-dose regimens of Ad26.ZEBOV (adenovirus serotype 26 [Ad26]) and MVA-BN-Filo (modified vaccinia Ankara [MVA]) vaccines with booster vaccination at day 360. Healthy US adults (N = 164) randomized into 10 groups received saline placebo or standard or high doses of Ad26 or MVA in 2-dose regimens at 7-, 14-, 28-, or 56-day intervals; 8 groups received booster Ad26 or MVA vaccinations on day 360. Participants reported solicited and unsolicited reactogenicity; we measured immunoglobulin G binding, neutralizing antibodies and cellular immune responses to Ebola virus glycoprotein. All regimens were well tolerated with no serious vaccine-related adverse events. Heterologous (Ad26,MVA [dose 1, dose 2] or MVA,Ad26) and homologous (Ad26,Ad26) regimens induced humoral and cellular immune responses 21 days after dose 2; responses were higher after heterologous regimens. Booster vaccination elicited anamnestic responses in all participants. Both heterologous and homologous Ad26,MVA Ebola vaccine regimens are well tolerated in healthy adults, regardless of interval or dose level. Heterologous 2-dose Ad26,MVA regimens containing an Ebola virus insert induce strong, durable humoral and cellular immune responses. Immunological memory was rapidly recalled by booster vaccination, suggesting that Ad26 booster doses could be considered for individuals at risk of Ebola infection, who previously received the 2-dose regimen.
Sections du résumé
BACKGROUND
This phase 1 placebo-controlled study assessed the safety and immunogenicity of 2-dose regimens of Ad26.ZEBOV (adenovirus serotype 26 [Ad26]) and MVA-BN-Filo (modified vaccinia Ankara [MVA]) vaccines with booster vaccination at day 360.
METHODS
Healthy US adults (N = 164) randomized into 10 groups received saline placebo or standard or high doses of Ad26 or MVA in 2-dose regimens at 7-, 14-, 28-, or 56-day intervals; 8 groups received booster Ad26 or MVA vaccinations on day 360. Participants reported solicited and unsolicited reactogenicity; we measured immunoglobulin G binding, neutralizing antibodies and cellular immune responses to Ebola virus glycoprotein.
RESULTS
All regimens were well tolerated with no serious vaccine-related adverse events. Heterologous (Ad26,MVA [dose 1, dose 2] or MVA,Ad26) and homologous (Ad26,Ad26) regimens induced humoral and cellular immune responses 21 days after dose 2; responses were higher after heterologous regimens. Booster vaccination elicited anamnestic responses in all participants.
CONCLUSIONS
Both heterologous and homologous Ad26,MVA Ebola vaccine regimens are well tolerated in healthy adults, regardless of interval or dose level. Heterologous 2-dose Ad26,MVA regimens containing an Ebola virus insert induce strong, durable humoral and cellular immune responses. Immunological memory was rapidly recalled by booster vaccination, suggesting that Ad26 booster doses could be considered for individuals at risk of Ebola infection, who previously received the 2-dose regimen.
Identifiants
pubmed: 32939546
pii: 5906668
doi: 10.1093/infdis/jiaa586
pmc: PMC9441209
doi:
Substances chimiques
Antibodies, Viral
0
Ebola Vaccines
0
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
595-607Subventions
Organisme : NIAID NIH HHS
ID : HHSN272200800056C
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
JAMA. 2016 Apr 19;315(15):1610-23
pubmed: 27092831
J Infect Dis. 2019 Jun 5;220(1):46-56
pubmed: 30796818
N Engl J Med. 2016 Aug 11;375(6):587-96
pubmed: 27509108
J Clin Invest. 2012 Jan;122(1):359-67
pubmed: 22201684
PLoS One. 2012;7(12):e44115
pubmed: 23236343
Lancet. 2019 Mar 2;393(10174):936-948
pubmed: 30777297
Sci Transl Med. 2014 Nov 5;6(261):261ra153
pubmed: 25378645
Lancet. 2018 Jul 21;392(10143):232-243
pubmed: 30047376
Lancet Infect Dis. 2019 Aug;19(8):813-814
pubmed: 31345457
J Infect Dis. 2012 Mar 1;205(5):772-81
pubmed: 22275401
Infect Immun. 2010 Jan;78(1):145-53
pubmed: 19858306
PLoS One. 2012;7(2):e31208
pubmed: 22363582
J Virol. 2011 May;85(9):4222-33
pubmed: 21325402
Philos Trans R Soc Lond B Biol Sci. 2017 May 26;372(1721):
pubmed: 28396468
Elife. 2015 Nov 03;4:
pubmed: 26525597
Lancet. 2017 Feb 4;389(10068):505-518
pubmed: 28017403
Nat Med. 2011 Aug 21;17(9):1128-31
pubmed: 21857654
J Infect Dis. 2019 Jun 5;220(1):57-67
pubmed: 30796816